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Microbeam radiation therapy (MRT) is an irradiation modality for therapeutic purposes which uses ar-
rays of collimated quasi parallel microbeams, each up to 100 mm wide, to deliver high radiation doses.
Several studies have reported the extraordinary tolerance of normal tissues to MRT irradiation;
conversely, MRT has been shown to be highly efﬁcient on tumor growth control. The original and most
widely developed application of MRT, yet in the preclinical phase, consists in using spatially fractionated
X-ray beams issued from a synchrotron radiation source in the treatment of brain tumors. More recently,
MRT has been tested in successful pioneering assays to reduce or interrupt seizures in preclinical models
of epilepsy. The MRT concept has also been extended to proton therapy. The development of MRT to-
wards its clinical implementation is presently driven by an EU-supported consortium of laboratories
from 16 countries within the COST Action TD1205 (SYRA3). The results of the ﬁrst SYRA3 workshop on
“Radiation Therapy with Synchrotron Radiation: Achievements and Challenges” held in Krakow (Poland)
during March 25e26 2014 are summarized in this issue with an overview presented in this paper. The
papers reﬂect the multidisciplinary international activities of SYRA3. The topics covered in this focus
issue include medical physics aspects, pre-clinical studies, clinical applications, and an industrial
perspective; ﬁnally an outlook towards future prospects of compact sources and proton microbeams.
© 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).To build an international interdisciplinary platform for collab-
orative research in synchrotron radiation therapy, the COST Action
“Innovative Methods in Radiotherapy and Radiosurgery using Syn-
chrotron Radiation (SYRA3)” of the European Cooperation in Science
and Technology (COST) was launched in May 2013 (http://www.
syra3.eu). SYRA3 includes the preparation of clinical trials using
orthovoltage X-ray microbeam radiotherapy (MRT) at the European
Synchrotron Radiation Facility (ESRF) in Grenoble, France.
MRT, a concept developed about 25 years ago at the National
Synchrotron Light Source at Brookhaven National Laboratory (BNL)
on Long Island (New York, USA), is based on irradiation for thera-
peutic purposes by orthovoltage synchrotron X-rays that are
spatially fractionated by a collimator into an array of parallel mi-
crobeams, each up to 100 mm wide. With its highly collimatedel.Olko@ifj.edu.pl (P. Olko),
tum.de (J.J. Wilkens).
alf of Associazione Italiana di Fisicmicrobeams and the characteristically high skin entrance doses it
can be considered as a special type of radiosurgery.
The MRT concept was ﬁrst explored with reference to experi-
ments that had been carried out by Howard J. Curtis and his col-
leagues at BNL during the 1950s to simulate the biological effects of
cosmic ray primaries [1]. They had shown that a single cylindrical,
25 mm wide, cyclotron-generated 22.5 MeV deuteron beam
imparting absorbed doses of over 10,000 Gy to a microcylinder of
mouse brain tissue during a single exposure resulted in loss of most
targeted nuclei with neither loss of neuropil along the ﬁrst 1.5 mm
of its path through the superﬁcial visual cortex of the mouse, nor
obvious changes of the animal's behavior. Thus around 1990, Per O.
Spanne, a radiation physicist and microtomography researcher, and
Daniel N. Slatkin, an anatomic pathologist and boron neutron-
capture therapy (BNCT) researcher, both at BNL, informed of
those studies, decided to deliver a dose of about 200 Gy to the head
of a normal mouse using Spanne's pencil microtomography beam
at BNL's National Synchrotron Light Source (NSLS) (unpublished).
The mouse recovered normally from anesthesia and wasa Medica. This is an open access article under the CC BY-NC-ND license (http://
A. Bravin et al. / Physica Medica 31 (2015) 561e563562euthanized after its otherwise unremarkable life one month later;
no histopathological evidence of brain damage in the region of the
single beam's path was detected by light-microscopy. But 4 mm
high, 25 mm wide, “microplanar” beamlets of 50e150 keV syn-
chrotron X-rays at the NSLS were shown to cause microscopically
detectable brain lesions in rats similar to those described by Curtis
and his colleagues. Brain tissue tolerance experiments at BNL
revealed that normal Mongolian gerbils (unpublished) and normal
rats withstood absorbed doses of hundreds, even thousands of gray
from such beamlets delivered to noncontiguous, quasi parallel
microscopic slices of their CNS tissues [2,3]. The theoretical possi-
bility of radiosurgery by irradiating parallel arrays of such micro-
slices spaced 50e200 mm apart, crossﬁring the array through the
tumors from several ports, was then investigated and tested for a
malignant rat brain tumor at BNL with encouraging results [4].
Astonishingly, it was noticed that some tumors were ablated in rats
irradiated unidirectionally. However, despite these exciting pio-
neering results, the MRT programwas not further supported by the
BNL. Accordingly, a Swiss-based research group for MRT (Hans
Blattmann, Jan-Olaf Gebbers, Jean A. Laissue, Daniel N. Slatkin, Per
O. Spanne, Hans Peter Wagner) presented the MRT concept on June
12,1992 to Professors Haensel, Altarelli and Br€anden, then directors
of the ESRF, which was under construction in Grenoble, France.
Spanne began developingMRTat the ESRF in September 1994 using
a single-slit collimator. The ﬁrst dimensionally adjustable multislit
microcollimator (MSC) [5], was manufactured in Canada by David
W. Archer (US Patent 5,771,270; 1998), then moved to the ESRF's
ID17 biomedical beamline. It was used for irradiations of intrace-
rebral 9L rat gliosarcomas, of the hindbrains of normal suckling rats
and of weanling piglets, thus avoiding the time-consuming trans-
lation of anesthetized animals back and forth across a single
microbeam. Despite its dimensional irregularities, experimental
and theoretical studies proved the Archer MSC very useful for
in vivo preclinical MRT studies and Monte Carlo therapy planning.
Spanne's tragic death in an airplane crash on September 2, 1998
determined signiﬁcant changes in the microbeam research pro-
gram at the ESRF.
MRT has attracted the attention of several research groups
internationally; it has been investigated in many experiments, with
modiﬁcations of a host of parameters such as geometry of the
beamlets, number of ports, dose, microdosimetry; adjuvants and
radiation enhancers have been added. Normal tissue tolerance,
bystander effects, basic radiobiological developments in several
species, therapeutic ratios for a range of experimental tumors of
small laboratory animals, postirradiation memory and other as-
pects have been tested, mainly in rodents. Collimators and de-
tectors have been developed speciﬁcally for MRT. New
mathematical models have been designed and investigated using
Monte Carlo dose simulations. A therapy planning system adapted
from commercial therapy planning software, speciﬁcally geared to
the technical parameters and requirements of synchrotron based
MRT, is currently being developed. The ESRF now has an MRT fa-
cility for animal and clinical studies, including an elaborate patient
safety system. To bridge the gap between MRT research on small
animals and human patients, a pet animal patient trial based in
Switzerland and France has been initiated. Pet animals such as cats
and some breeds of dogs develop spontaneous malignant tumors
very similar to those seen in human patients. Radiation therapy for
animal tumors has become an established part of veterinary
medicine in several countries for more than a decade. Some canine
tumors are so similar to their human counterparts both in their
histological signature and in the dynamics of their growth that they
are considered excellent platforms to answer one of the key
questions about safety and efﬁcacy of MRT before a clinical trial
would be initiated:Will such spontaneous tumors in larger animalsrespond to MRT as well as the much smaller, orthotopically
implanted malignancies in rodents? Answering this question is a
major logistic challenge because of the sporadic occurrence and the
diversity of spontaneous tumors in dogs and cats, not to mention
the restricted availability for post-therapy follow-up by pet owners.
A signiﬁcantly shorter hospitalization time for tumor patients is
a major advantage of radiosurgery over temporally fractionated
radiotherapy. The quality of life, particularly in very young children
with tumors of the brain or the spinal cord, might be improved if
the same degree of palliation could be achieved with single-
fraction radiosurgery, instead of six weeks of daily radiotherapy
requiring daily anaesthesia. Much work needs to be done toward
that goal.
We are pleased to present the ﬁrst manuscript collection
exclusively dedicated to synchrotron-based radiation therapy. The
wide range of topics presented in this collection, based on pre-
sentations held at the 1st SYRA3 COST Conference Radiation Ther-
apy with Synchrotron Radiation: Achievements and Challenges, with
support of the Institute of Nuclear Physics at the Polish Academy of
Sciences in the beautiful city of Krakow in March 2014, reﬂects the
multidisciplinary international activities of SYRA3. The topics
covered in this focus issue range from medical physics aspects [6]
over pre-clinical studies [7e11] towards clinical applications
[12,13] including an industrial perspective [14], and ﬁnally an
outlook towards future prospects of compact sources [15] and
proton microbeams [16].
Several publications have shown that the healthy vascular
network is highly resistant to hectogray doses of radiation when
delivered in arrays of micrometric-wide microbeams. The same
resistance was instead not found in tumoral vasculature; this evi-
dence has led to identify the anti-vascular effects to lead to tumor
control by MRT. The paper by Bouchet et al. [7] reviews the most
signiﬁcant results of the effects of MRTon vasculature performed in
different animal models.
Romanelli et al. [11] studied the short term effect of microbeam
transections of the brain cortex. They irradiated the visual brain
cortex regions in rodents to create microscopically narrow lesions
(5 mm in thickness and spaced of 200 mm center-to-center). The
procedure, well tolerated by rats, determined an incision-like path
of neuronal loss while adjacent non irradiated columns remained
intact. For the authors, these preliminary ﬁndings suggest that
microbeam radiosurgery can affect the cortex at a cellular level
providing a potential novel and attractive tool to study cortical
function.
Grotzer et al. [12] discussed the candidate populations for the
clinical application of MRT. They identiﬁed two targets in adults
with glioblastomamultiforme and in pediatric patients with diffuse
intrinsic pontine glioma. Both tumors are extremely difﬁcult to
manage with currently available therapy with overall little or no
success, regardless of the therapeutic approach used [12].
In the current clinical practice of radiosurgery, treatment is
usually deﬁned by the total physical dose to an iso-surface which is
conformed as close as possible to the gross tumor volume. In the
paper by Millar et al. [13] the concept of biologically effective dose
(BED) on treatment planning is discussed: BED allows a physical
dose to be converted into a dose that describes the biological effect
of the radiation on tumor or normal tissue and it takes into account
also the repair of sublethal damage. This concept could be impor-
tant to compare the effects of MRT versus other established
techniques.
Bystander effects are thought to play an important role in MRT.
Fernandez-Palomo et al. [8] investigated the bystander and
abscopal effects in rats after MRT. Their ﬁndings strongly suggest
that bystander effects (in partner animals) are not the same as
abscopal effects (in the irradiated animal). Also, they have observed
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modulate the abscopal effect in other organs of the directly irra-
diated animal and modify bystander response in unirradiated
companion cage mates.
Br€auer-Krisch et al. [6] reviewed the medical physics aspects of
radiotherapy with synchrotron radiation, giving particular
emphasis to the dosimetry, microdosimetry and dose rate. A large
team of international experts discussed the different methods for
relative and absolute 2D and 3D dosimetry, including ﬁlm, gels and
solid state detectors for monochromatic and polychromatic energy
deposition measurements.
Studer et al. [10] discussed the use of interlaced microbeams
delivered to the somatosensory cortex to control the seizures in a
genetic model of absence epilepsy. These antiepileptic effects were
stable over 4 months and with low tissular and functional side-
effects; the parcellization of the cortex prevented the pyramidal
neurons, still physiological active, to synchronize. The method
needs more tests on rodents and on non-human primates before
potentially moving to treat pharmaco-resistant epilepsies in
humans. The pathway and the potential targets are here presented.
Girst et al. [9] and Kłodowska et al. [16] extended the concept of
microbeam to protons using an experimental [9] or a theoretical
approach [16]. Girst et al. [9] used the ion microprobe SNAKE in
Munich, able to produce focused proton microbeams (“proton
microchannels”) with the ﬁnal aim of improving the normal tissue
protection. This paper presents the ﬁrst direct comparison between
X-ray and proton microbeams, by irradiating skin tissues with a
mean dose of 2 Gy either with parallel synchrotron-generated X-
ray beams at the ESRF or with 20 MeV protons at SNAKE. Skin
irradiation using either X-ray or proton microchannels maintain a
higher cell viability and DNA integrity compared to a homogeneous
irradiation, and thus might improve normal tissue protection after
radiation therapy.
Kłodowska et al. [16] simulated proton microchannels of energy
between 60 and 120 MeV and calculated the peak to valley dose
ratios in a human head phantom at different depths considering
different irradiation geometries. The obtained PVDR values are
comparable with photonMRT data over depths of some 15e25 mm
in tissue. Their ﬁndings suggest that by combining several ports it is
possible to signiﬁcantly boost the absorbed dose in the target
volume, which needs to be conﬁrmed by biology and radiobiology
studies of normal and tumor tissues.
MRT is presently possible only at synchrotron radiation sources.
The dissemination of the technique outside these large facilities
will be possible only thanks to the presence of investments by the
industry to produce easy-to-use and reliable radiotherapy units to
be installed in the vicinity of large hospital centers. These subjects
are discussed respectively in the paper by Wright [14] and Jacquet
and Suortti [15].
Wright [14] examines the problems associated with the clinical
implementation ofMRT in hospitals, using dedicatedmachines able
to deliver the MRT treatment. The paper discusses several irradia-
tion parameters, including the beam size and energy and the irra-
diation geometry. It also identiﬁed lung cancer, one of the cancers
with a very high incidence, as a target of primary interest from a
population impact point of view. MRT might be of high interest in
lung treatment if ﬁnally demonstrated that it can reduce radiation-
induced ﬁbrosis.Jacquet and Suortti [15] present the characteristics of inverse
Compton scattering X-ray sources, the compact X-ray machines
presently under construction at different sites around theword. For
ThomX, presently under construction in Orsay (France), the possi-
bility of performing Stereotactic Synchrotron Radiation Therapy
using quasi monochromatic X-rays is discussed from a beam ﬂux
point of view. Calculations show that ThomX has the potential of
serving as the radiation source in future radiation therapy pro-
grams, and therefore it possess the characteristics to be integrated
in hospital environment.
Should you have interest in the potential clinical applications of
MRT we recommend the COST Actionwebsite http://www.syra3.eu
for further information. We should be pleased to welcome you to
our conferences or workshops and hope that you enjoy reading this
issue of Physica Medica e European Journal of Medical Physics.Acknowledgments
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